BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11740992)

  • 1. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
    Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
    Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.
    Hazuka MB; Turrisi AT; Lutz ST; Martel MK; Ten Haken RK; Strawderman M; Borema PL; Lichter AS
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):273-84. PubMed ID: 8407401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study.
    Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK
    J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
    Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
    Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).
    Rowell NP; Williams CJ
    Cochrane Database Syst Rev; 2001; (1):CD002935. PubMed ID: 11279780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
    Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
    Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
    Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
    Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
    Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study.
    Hatton MQ; Hill R; Fenwick JD; Morgan SA; Wilson PC; Atherton PJ; Dickson J; Murray KE; Paul J
    Radiother Oncol; 2016 Mar; 118(3):471-7. PubMed ID: 26687902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical radiotherapy in stage I non-small cell lung cancer (NSCLC)--Singapore National Cancer Centre experience.
    Low JSh; Koh WY; Yap SP; Fong KW
    Ann Acad Med Singap; 2007 Sep; 36(9):778-83. PubMed ID: 17925989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).
    Rowell NP; Williams CJ
    Cochrane Database Syst Rev; 2001; (2):CD002935. PubMed ID: 11406051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
    Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
    Nyman J; Bergman B; Mercke C
    Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.